PE Fund Investments
Saimirra Innopharm raises Rs.160-Cr from Piramal Alternatives
Chennai-based pharmaceutical company Saimirra Innopharm has raised INR 160 crore from Piramal Alternatives (through Piramal’s India Credit Opportunities Fund II - PCF II), the fund management arm of the Piramal Group.The proceeds will be used to support Saimirra’s growth strategy, which includes brand acquisitions and entry into new therapeutic areas across domestic and international markets.Saimirra Innopharm operates in both domestic and international pharmaceutical markets. Its ROW (Rest of the World) division supplies more than 275 products across 70 countries. The domestic business, branded under Delvin Formulations, includes more than 20 brands.
Want to receive such news items in your inbox? Click Here to sign up for a trial.
